<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HPV vaccine hesitancy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/hpv-vaccine-hesitancy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 10 Sep 2025 15:25:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>HPV vaccine hesitancy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>UMD Researchers Leverage AI to Enhance Confidence in HPV Vaccination</title>
		<link>https://bioengineer.org/umd-researchers-leverage-ai-to-enhance-confidence-in-hpv-vaccination/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 10 Sep 2025 15:25:08 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI in public health]]></category>
		<category><![CDATA[cancer prevention strategies]]></category>
		<category><![CDATA[chatbot health interventions]]></category>
		<category><![CDATA[HPV vaccine hesitancy]]></category>
		<category><![CDATA[parental communication strategies]]></category>
		<guid isPermaLink="false">https://bioengineer.org/umd-researchers-leverage-ai-to-enhance-confidence-in-hpv-vaccination/</guid>

					<description><![CDATA[Human papillomavirus (HPV) vaccination represents a critical breakthrough in cancer prevention, yet its uptake among adolescents remains disappointingly low. Despite overwhelming evidence supporting the vaccine’s safety and efficacy against multiple types of cancer—including cervical, anal, and oropharyngeal cancers—only about 61% of teenagers aged 13 to 17 in the United States have received the recommended doses. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268351</post-id>	</item>
	</channel>
</rss>
